The AHA May 14 urged the Senate Finance Committee to take steps to strengthen the supply chain for essential pharmaceutical and other medical products. In comments to the committee for a hearing on supply chains, the AHA called for tariff exceptions to continue for pharmaceuticals and pharmaceutical products and that additional exceptions be added for medical devices and other critical care supplies.   
  
“Mitigating supply chain challenges requires diversifying where raw materials are sourced and where products are manufactured,” the AHA wrote. “Imposing tariffs that limit the U.S.’s ability to acquire constituent parts or finished medical and pharmaceutical products from abroad will hinder supply chain resiliency.”  
  
The AHA also urged Congress to reintroduce the Mapping America’s Pharmaceutical Supply Act, legislation that would create a plan for the Food and Drug Administration and the Department of Defense to map the U.S. pharmaceutical supply chain, and the Pharmaceutical Supply Chain Risk Assessment Act, a bill that would require a comprehensive risk assessment of the pharmaceutical supply chain. 

Related News Articles

Headline
The AHA provided a statement of record to the Senate Special Committee on Aging for a hearing Oct. 8 on the pharmaceutical and medical device supply chains.…
Headline
President Trump, late Sept. 25, announced that starting Oct. 1, the U.S. will impose a 100% tariff on any branded or patented pharmaceutical product, unless a…
Headline
The Department of Commerce Sept. 24 released a notice seeking public comment on an investigation it launched Sept. 2 on imports of personal protective…
Headline
The Food and Drug Administration has identified a Class I recall of certain Olympus ViziShot 2 FLEX Needles due to a possible patient safety issue caused by a…
Headline
The White House Sept. 5 issued an executive order modifying the scope of reciprocal tariffs announced in April to establish a framework of trade deals with…
Headline
A JAMA study published Aug. 20 found that nearly 63% of all U.S. drug production facilities from 2019 through 2024 were in counties where a weather disaster…